Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Corbus Pharmaceuticals Holdings Inc.

NAS: CRBP

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Corbus Pharmaceuticals Holdings Inc.

After Hours

 --Quotes are delayed by 20 min

Aug 12, 2020, 7:59 p.m.

CRBP
/zigman2/quotes/201549545/composite

$

7.29

Change

+0.18 +2.53%

Volume

Volume 16,209

Quotes are delayed by 20 min

/zigman2/quotes/201549545/composite

Previous close

$ 6.96

$ 7.11

Change

+0.15 +2.16%

Day low

Day high

$7.01

$7.37

Open

52 week low

52 week high

$3.29

$8.78

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Corbus Pharmaceuticals Holdings Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Sales/Revenue 648,3821.91M2.44M4.82M36.14M
Cost of Goods Sold (COGS) incl. D&A -----
COGS excluding D&A -----
Depreciation & Amortization Expense 43,94387,664255,652493,9381.23M
Depreciation 43,94387,664255,652493,9381.23M
Amortization of Intangibles -----
Gross Income -----
20152016201720182019 5-year trend
SG&A Expense 9.46M21.81M34.75M61.08M116.6M
Research & Development 5.89M15.44M26.04M48.61M94.19M
Other SG&A 3.57M6.37M8.71M12.46M22.41M
Other Operating Expense -----
Unusual Expense ---191,244-
EBIT after Unusual Expense ---(56.94M)-
Non Operating Income/Expense 1,980(14,090)(41,910)284,0404.42M
Non-Operating Interest Income 3,4174,878196,487990,2081.25M
Equity in Affiliates (Pretax) -----
Interest Expense 2,4404,40113,3757,43119,025
Gross Interest Expense 2,4404,40113,3757,43119,025
Interest Capitalized -----
Pretax Income (8.85M)(20M)(32.42M)(55.67M)(76.04M)
Income Tax ----(4.58M)
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits ----4.58M
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (8.85M)(20M)(32.42M)(55.67M)(71.45M)
Minority Interest Expense -----
Net Income (8.85M)(20M)(32.42M)(55.67M)(71.45M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (8.85M)(20M)(32.42M)(55.67M)(71.45M)
Preferred Dividends -----
Net Income Available to Common (8.85M)(20M)(32.42M)(55.67M)(71.45M)
EPS (Basic) (0.28)(0.49)(0.65)(0.98)(1.12)
Basic Shares Outstanding 31.35M41.14M50.18M57M63.9M
EPS (Diluted) (0.28)(0.49)(0.65)(0.98)(1.12)
Diluted Shares Outstanding 31.35M41.14M50.18M57M63.9M
EBITDA (8.81M)(19.9M)(32.31M)(56.25M)(80.46M)
Copyright 2020 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.